Patients with severe or moderate disorder of sex development (DSD) with a inconclusive molecular diagnosis will benefit from optical genome mapping analysis.~A venous blood sample on ethylenediaminetetraacetic acid (EDTA) tube (5mL) will be taken in order to extract the DNA that will be used for the optical genome mapping analysis.
The goal of this clinical trial is to identify structural variants by Optical Genome Mapping (OGM) in the described participant population.~The main questions it aims to answer are:~Identify constitutional structural variants by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive.~Identify mosaic structural variants (present in a subpopulation of somatic cells only) by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive.~Compare the diagnostic yields of OGM and of Comparative Genome Hybridization Array (CGH array) methods.~Compare the diagnostic yields of the OGM and of Whole Genome Sequencing (National Sequencing Program), only if performed.~Participants will be required to:~a follow-up interview with a physician to review their own and family medical and surgical history, with a focusing on DSD.~An interview to assess their exposure to environmental pollutants during fetal life, using a validated questionnaire.~a blood test with a 5mL tube to perform optical genome mapping analysis.